

**UNITAID Executive Board****20<sup>th</sup> Session****12 - 13 June 2014****WHO Headquarters, Salle C****Geneva, Switzerland****Resolution n° 4****Medicines Patent Pool**

The Board takes note of the final report of the independent **Strategic Review of the Medicines Patent Pool** conducted by CEPA contained in document UNITAID/EB20/2014/15: "Update on Medicines Patent Pool" and commends the MPP's important achievements.

The Board instructs the Secretariat to invite the MPP to develop a new multi-year funding proposal for the continued implementation of the MPP's existing mandate beyond the end of 2015. The proposal should include a proposed methodology to evaluate impact, together with a clear rationale demonstrating that the proposal represents clear value for money. It should be submitted by 30 September 2014, for PRC review in October and consideration at the UNITAID Executive Board meeting in December 2014.

In addition, the Board also instructs the Secretariat to ask the MPP to prepare feasibility studies including risk assessments examining scenarios for the possible inclusion of TB and HCV as new disease areas to be addressed by the MPP. The studies should also include a projection of the resource implications for the MPP.

The Board underlines its commitment to supporting the MPP's financial sustainability and in this context, instructs the Secretariat to request the MPP to develop a further feasibility study including a risk assessment exploring options for the diversification of its funding. The study should also specifically address eventual options for funding in the event of the inclusion of TB and HCV as new disease areas to be addressed by the MPP.

The three feasibility studies should be submitted to UNITAID by 30 April 2015, for PRC review and consideration at the UNITAID Executive Board meeting in June 2015.

A handwritten signature in blue ink, appearing to read "P. Douste-Blazy".

Philippe Douste-Blazy  
Chair of the UNITAID Executive Board